Dual therapy of daclatasvir and asunaprevir produces SVR12 in phase 3 trial

  • April 23, 2014

LONDON — Hepatitis C virus genotype 1b-infected patients given a dual therapy of daclatasvir and asunaprevir for 12 or 24 weeks achieved a sustained virologic response, according to research from a phase 3 trial presented at the International Liver Congress.

Researchers analyzed 643 patients who received both 60 mg of daclatasvir (DVC) QD and 100 mg of asunaprevir (ASV) BID. Treatment naive patients (n=203) received the dual therapy or matching placebos (102) for 12 weeks, whereas null/partial responders (n=205) and ineligible/intolerant of peginterferon/ribavirin (n=235) received dual therapy for 24 weeks. The DVC and ASV treatment naive group continued treatment through 24 weeks, whereas the placebos entered a different study after 12 weeks. Seventy-one percent of patients were IL28B non-CC; 30% were cirrhotic. The primary endpoint was sustainable virologic response at 12 weeks (SVR12).

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
  • Health Care Update
  • ARNOLD AND PORTER SILO
  • Medicare lab payments
  • New law will modernize Medicare lab payments: What physicians need to know. Analysis from Arnold & Porter LLP.
More »
HCV Next